Candel Therapeutics (CADL) Other Non-Current Assets (2020 - 2025)
Candel Therapeutics (CADL) reported Other Non-Current Assets of $416000.0 for Q4 2025, up 56.39% on a YoY basis from $266000.0 in Q4 2024, and up 56.39% sequentially from $266000.0 in Q3 2025.
Candel Therapeutics (CADL) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Other Non-Current Assets data on file, last reported at $416000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets rose 56.39% year-over-year to $416000.0; the trailing twelve-month figure through Dec 2025 stood at $416000.0 (up 56.39% YoY), and the FY2025 full-year result was $416000.0, up 56.39% from the prior year.
- Other Non-Current Assets climbed to $416000.0 in Q4 2025, from $266000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q2 2021 to a low of $58000.0 in Q1 2025.
- A 5-year average of $355210.5 and a median of $266000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets tumbled 84.46% in 2022 and surged 129.31% in 2024, its largest moves.
- Tracing CADL's Other Non-Current Assets over 5 years: stood at $400000.0 in 2021, then dropped by 25.0% to $300000.0 in 2022, then tumbled by 61.33% to $116000.0 in 2023, then surged by 129.31% to $266000.0 in 2024, then jumped by 56.39% to $416000.0 in 2025.
- Business Quant data shows CADL's Other Non-Current Assets at $416000.0 in Q4 2025, $266000.0 in Q3 2025, and $266000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | 416,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 416,000.00 |
| Sep 30, 2025 | 266,000.00 |
| Jun 30, 2025 | 266,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 116,000.00 |
| Sep 30, 2023 | 266,000.00 |
| Jun 30, 2023 | 159,000.00 |
| Mar 31, 2023 | 266,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | 266,000.00 |
| Jun 30, 2022 | 266,000.00 |
| Mar 31, 2022 | 437,000.00 |
| Dec 31, 2021 | 400,000.00 |
| Sep 30, 2021 | 423,000.00 |
| Jun 30, 2021 | 1.71 Mn |
| Dec 31, 2020 | 349,000.00 |